USFDAJul 29, 2026, 07:03 AM
Ocugen OCU410 Receives FDA RMAT Designation for Geographic Atrophy
AI Summary
Ocugen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational product OCU410 for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). This designation, supported by positive Phase 2 clinical data, is expected to expedite the regulatory path for OCU410, which is being developed as a one-time gene therapy. The company has aligned with the FDA on the Phase 3 trial design, with initiation expected in Q3 2026 and a BLA filing anticipated in 2028.
Key Highlights
- Ocugen's OCU410 received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
- The designation is for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD).
- RMAT designation was supported by Phase 2 clinical data showing efficacy and a favorable safety profile.
- The designation allows for expedited development and potential for accelerated approval and Priority Review.
- FDA alignment on OCU410 Phase 3 registrational trial design was reached in early July 2026.
- Phase 3 trial initiation is expected in Q3 2026.
- Biologics License Application (BLA) filing is anticipated in 2028.
- Geographic atrophy affects an estimated 2 to 3 million people in the U.S. and Europe.
Price Impact
More from OCGN